Atavistik Bio and Roche sign allosteric drug discovery collaboration worth up to $1.9bn

The collaboration gives Roche access to Atavistik Bio's AMPS platform to discover allosteric small molecules across cardiovascular, renal and metabolic disease targets.

Roche and Atavistik Bio have entered a multi-target research collaboration using Atavistik's AMPS platform to identify and develop allosteric small-molecule therapies.

Atavistik will receive $70 million upfront and could earn up to $1.9 billion in milestone payments, as well as tiered royalties on resulting products.

Field	Content
Field	Content
Alert Type	Research Collaboration
Companies	Atavistik Bio; Roche
Deal Type	Multi-target research collaboration
Technology/Platform	AMPS allosteric drug discovery platform
Therapy Areas	Cardiovascular, renal and metabolic diseases
Technology/Modality	Allosteric small molecules
Upfront Payment	$70 million
Potential Milestones	Up to $1.9 billion
Additional Economics	Tiered royalties
What Happened	Roche entered a collaboration with Atavistik Bio to discover and develop allosteric small-molecule therapies against multiple targets.
Why It Matters	The agreement pairs Roche's drug-development capabilities with Atavistik's platform for identifying allosteric binding opportunities.
Strategic Rationale	The collaboration is designed to generate new medicines against cardiovascular, renal and metabolic disease targets.
Potential Impact	Successful programmes could broaden Roche's pipeline while validating Atavistik's AMPS platform across multiple targets.
Key Takeaway	The collaboration carries potential economics of nearly $2 billion in upfront and milestone payments before royalties.
What to Watch	Target progression, candidate nominations and movement of programmes into clinical development.
Primary Source	Atavistik Bio
Relevant Date	24 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com